Founder and CEO of Anti-Doping Research Professor Emeritus of Molecular and Medical Pharmacology at the UCLA David Geffen School of Medicine
Position:
Con to the question "Should performance enhancing drugs (such as steroids) be accepted in sports?"
Reasoning:
"If you try to get every last little cheater, you're going to be pretty frustrated. There are always going to be ways to beat testing. But if you don't test, sport is gone, it really is. Then you might say, well, OK, everybody is going to be on drugs, and they will all be equal again. But people will start getting really sick. All these things are toxic."
"The Steroid Detective," US News and World Report, Dec. 12, 2004
Experts
Individuals with MDs, JDs, PhDs, or other relevant advanced degrees, heads of professional sports leagues, and US Congress members with significant involvement in, or related to, performance enhancing drugs and sports. [Note: Experts definition varies by site]
Involvement and Affiliations:
Chairman, Equine Drug Research Institute's Scientific Advisory Committee, 2008-present
Professor Emeritus, Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, 2007-present
Founder and CEO, Anti-Doping Research, 2005-present
Member, International Olympic Committee Medical Commission, 1988-present
Member, World Anti-Doping Agency Health, Medical and Research Committee, 2006-2008
Cowritten with G. Green and C.K. Hatton, "Drugs in Sport," The Olympic Textbook of Medicine in Sport, 2008
Cowritten with Y.-C. Chang, B. Starcevic, and C.K. Hatton, "LC-MS Measurement of Anabolic Steroids," Chromatographic Methods in clinical Chemistry and Toxicology, eds. R.L. Bertholf and R.E. Winecker, 2007
Cowritten with G. Green, M.H. Sekera, P. Scott, and B. Starcevic, "False Positive EPO Test Concerns Unfounded," Letter to the editor, Blood, Sep. 2006
Cowritten with B. Starcevic, Y.-C. Chang, and C.K. Hatton, "Sports Doping Analysis Using LC-MS," Encyclopedia of Mass Spectrometry, eds. M.L. Gross and R. Caprioli, 2006
"Use and Abuse of Anabolic Steroids," Endocrinology, eds. L.J. DeGroot and J.L. Jameson, 2006
Cowritten with R. Jasuja, A. Miller, Y.-C. Chang, K.L. Herbst, B. Starcevic, J.N. Artaza, R. Singh, D. Datta, A. Sarkissian, C. Chandsawangbhuwana, M. Baker, and S. Bhasin, "Tetrahydrogestrinone Is an Androgenic Steroid That Stimulates Androgen Receptor-Mediated, Myogenic Differentiation in C3H10T1/2 Multipotent Mesenchymal Cells and Promotes Muscle Accretion in Orchidectomized Male Rats," Endocrinology, Oct. 2005
Cowritten with Y.-C. Chang, B. Starcevic, B.D. Ahrens, and J.M. Strouse, "Identification of a Urinary Metabolite of the Designer Steroid Tetrahydrogestrinone," 53rd American Society for Mass Spectrometry Conference, San Antonio, June 2005
Cowritten with C. Wang, B. Starcevic, D. Heber, C. Ambler, N. Berman, G. Lucas, A. Leung, K. Schramm, P.W. Lee, L. Hull, and R.S. Swerdloff, "Low Fat High Fiber Diet Decreased Serum and Urine Androgens in Men," Journal of Clinical Endocrinology & Metabolism, June 2005
Cowritten with M.H. Sekera, B.D. Ahrens, Y.-C. Chang, B. Starcevic, and C. Georgakopoulos, "Another Designer Steroid: Discovery, Synthesis, and Detection of 'Madol' in Urine," Rapid Communications in Mass Spectrometry, Mar. 30, 2005
Cowritten with Michael H. Sekera, Brian D. Ahrens, Borislav Starcevic, Yu-Chen Chang, and Caroline K. Hatton, "Tetrahydrogestrinone: Discovery, Synthesis, and Detection in Urine," Rapid Communications in Mass Spectrometry, June 2004
Cowritten with B.Z. Leder, B.D. Ahrens, C.K. Hatton, and J.S. Finkelstein, "Effects of Androstenedione Administration on Epitestosterone Metabolism in Men," Steroids, June 2002
Cowritten with R. Aguilera, and C.K. Hatton, "Detection of Epitestosterone Doping by Isotope Ratio Mass Spectrometry," Clinical Chemistry, Apr. 2002
Cowritten with B.Z. Leder, B. Ahrens, B. Starcevic, C.K. Hatton, G.A. Green, and J.S. Finkelstein, "Trace Contamination of Over-the-Counter Androstenedione and Positive Urine Test Results for a Nandrolone Metabolite," Journal of the American Medical Association, Nov. 2000
Cowritten with TH Murray, "Performance-Enhancing Drugs, Fair Competition, and Olympic Sport," Journal of the American Medical Association, July 1996
Other:
Oversaw the drug testing at the 2002 Winter Olympic Games in Salt Lake City, 1996 Summer Olympic Games in Atlanta (anabolic agents), 1994 Soccer World Cup, and 1984 Summer Olympic Games in Los Angeles
Involved in drug testing for the US Olympic Committee, National Collegiate Athletic Association (NCAA), Major League Baseball's minor leagues, and the National Football League
Developed the testing methodology that differentiates natural from artificial testosterone, inaugurated the test for darbepoetin (a form of EPO), first reported the use of a designer steroid (norbolethone) in sport, and, in the investigation of Bay Area Laboratory Co-operative (BALCO), first identified THG (a designer steroid)
